Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

Af­ter hit­ting a speed bump in its first at­tempt at de­vel­op­ing a gene ther­a­py for Friedre­ich’s atax­ia, Astel­las is ready to put a new ver­sion in the clin­ic.

On Thurs­day, the Japan­ese drug­mak­er an­nounced the FDA has cleared its IND for ASP2016. The com­pa­ny is hop­ing to dose the first pa­tient in the sec­ond half of 2024, ac­cord­ing to Richard Wil­son, who leads ge­net­ic reg­u­la­tion at Astel­las Gene Ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER